What are the recommendations for prescribing Fosamax (alendronate) to patients with known atherosclerotic plaque who also have osteopenia?

Fosamax (Alendronate) in Patients with Atherosclerotic Plaque and Osteopenia

Fosamax can be safely prescribed to patients with known atherosclerotic plaque and osteopenia, as recent high-quality evidence demonstrates no adverse effect on vascular calcification progression. The decision to treat should be based on fracture risk assessment, not the presence of vascular disease 1.

Key Evidence on Vascular Safety

The SALTIRE2 randomized controlled trial (2024) directly addressed this concern by examining whether alendronic acid affects coronary or aortic calcification in patients with existing cardiovascular disease 2. After 24 months of treatment, alendronic acid showed no difference in coronary calcium score progression compared to placebo (34 vs 16 Agatston units, P=0.99) and no difference in thoracic aorta calcium scores (116 vs 132 Agatston units, P=0.62) 2. Importantly, there was also no increase in calcification activity measured by 18F-sodium fluoride PET imaging 2.

This evidence directly refutes historical concerns that bisphosphonates might worsen vascular calcification due to their effects on calcium metabolism.

Treatment Indications for Osteopenia

According to the 2024 ACP guidelines, treatment decisions should follow this framework 1:

For Patients ≥40 Years Old:

• Moderate fracture risk: FRAX 10-year risk of major osteoporotic fracture (MOF) 10-20% or hip fracture 1-3%, OR BMD T-score between -1.0 and -2.4
• High fracture risk: BMD T-score ≤-2.5 but >-3.5, OR FRAX MOF ≥20% or hip ≥3%
• Very high fracture risk: Prior osteoporotic fracture, OR BMD T-score ≤-3.5, OR FRAX MOF ≥30% or hip ≥4.5%

The ACP strongly recommends oral bisphosphonates (including alendronate) over no treatment for patients at high and very high fracture risk 1. For moderate risk, bisphosphonates are conditionally recommended 1.

Practical Treatment Algorithm

1. Calculate FRAX score (adjusting for any glucocorticoid use if applicable - multiply MOF risk by 1.15 and hip risk by 1.2 if dose >7.5 mg/day) 3

2. Determine fracture risk category based on FRAX and BMD T-score

3. For moderate, high, or very high risk: Initiate alendronate 70 mg weekly 1

   • The presence of atherosclerotic plaque is NOT a contraindication 2
   • Standard dosing (70 mg weekly) is preferred over low-dose regimens for optimal efficacy 4

4. Ensure proper administration to minimize GI adverse events 5:

   • Take first thing in morning with full glass of plain water
   • Remain upright for at least 30 minutes
   • Take at least 30 minutes before first food, beverage, or other medication

Expected Outcomes

Alendronate treatment in osteopenia/osteoporosis produces:

• Lumbar spine BMD increase: 5-7% at 1-2 years 6, 4
• Femoral neck BMD increase: 2-4% at 1-2 years 6, 4
• Fracture risk reduction: 47% reduction in vertebral fractures in primary prevention 7

Important Caveats

Contraindications specific to the FDA label 5:

• Esophageal abnormalities that delay esophageal emptying (stricture, achalasia)
• Inability to stand or sit upright for at least 30 minutes
• Hypocalcemia (must be corrected before initiating therapy)

Common pitfalls to avoid:

• Do not withhold treatment solely due to presence of vascular calcification - this is not evidence-based 2
• Do not use "osteopenia" alone as indication - must assess fracture risk using FRAX and clinical factors 1
• Do not prescribe without ensuring patient can comply with strict administration instructions 5

Monitoring: Repeat BMD with vertebral fracture assessment every 1-2 years during therapy 3. Discontinuation should be considered after 3-5 years in patients who achieve adequate BMD improvement and remain at low fracture risk.

The evidence is clear: atherosclerotic plaque burden should not influence the decision to prescribe alendronate for osteopenia when fracture risk warrants treatment 2.